Highlightll Pharma’s Hong Kong IPO Application Lapses; Core Asset TLL-018 Enters Phase III Pivotal Trials
NewTimeSpace News: As disclosed by HKEX, the Main Board listing application of Hangzhou Highlightll Pharmaceutical Co., Ltd., filed on December 4, 2025, has recently lapsed upon expiry of the six-month review period. CICC and CMB International served as joint sponsors at the time of filing. Its core asset TLL-018 is the world’s sole highly selective TYK2/JAK1 inhibitor, now undergoing two Phase III registrational trials in China for chronic spontaneous urticaria and rheumatoid arthritis.
NewTimeSpace News: According to official HKEX filings, Highlightll’s Hong Kong Main Board IPO application submitted on December 4, 2025 has expired after the statutory six-month validity term, with CICC and CMB International appointed joint sponsors for the original submission.
Founded in 2017, Highlightll focuses on discovering and developing safe and effective therapeutics for patients suffering from autoimmune and inflammatory diseases globally. TLL-018, its lead candidate, is the world’s only highly selective TYK2/JAK1 inhibitor with potential to become a first-in-class and best-in-class treatment for chronic spontaneous urticaria and rheumatoid arthritis. Two Phase III registrational trials are ongoing in China, and the company targets NDA submission by the end of 2026.
Separately, self-developed TLL-041 is the world’s first and only brain-penetrant selective TYK2/JAK1 inhibitor indicated for neurodegenerative disorders. Its collaboration deal with Biohaven ranks as the largest disclosed transaction by total consideration in China’s neurodegenerative drug sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Highlightll Pharma Files for HKEX Listing, Core Product TLL-018 in Phase III Registrational Trials
- BlueFocus (300058.SZ): board resolves to terminate H-share offering and HKEX listing, sees no material adverse impact
- LONTIUM (688486.SH): CSRC accepts H-share filing, up to 23,878,000 shares for HKEX Main Board listing
- CHALIECO (02068.HK): wins EPC contract for 2.4 mtpa alumina project in Vietnam, contract price USD833 million
- CH GENERAL EDU (02175.HK): sets up wholly-owned unit to run AIGC training for art and design students
